Bugworks: GARDP commits $20 million for Bugworks' innovative compound to fight MDR bacteria
Bugworks Research has granted manufacturing and commercialisation rights for BWC0977 in as many as 146 countries, GARDP said
Read full article »
Bugworks is a California-based clinical-stage biopharmaceutical company that researches and develops novel therapeutics for the treatment of cancer and infectious diseases.
Read more